Analysts Anticipate Cardlytics Inc (CDLX) Will Post Quarterly Sales of $34.84 Million

Wall Street brokerages expect that Cardlytics Inc (NASDAQ:CDLX) will announce sales of $34.84 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Cardlytics’ earnings, with estimates ranging from $34.58 million to $35.23 million. The business is expected to announce its next earnings results on Thursday, August 9th.

On average, analysts expect that Cardlytics will report full-year sales of $154.65 million for the current financial year, with estimates ranging from $153.20 million to $155.59 million. For the next financial year, analysts forecast that the company will report sales of $246.82 million per share, with estimates ranging from $219.00 million to $263.10 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Cardlytics.

Get Cardlytics alerts:

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Thursday, May 10th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.02. The business had revenue of $32.71 million during the quarter, compared to analyst estimates of $29.74 million.

A number of research analysts recently weighed in on the stock. Gabelli restated a “buy” rating on shares of Cardlytics in a report on Monday, April 23rd. SunTrust Banks assumed coverage on shares of Cardlytics in a report on Tuesday, March 6th. They issued a “buy” rating and a $25.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on shares of Cardlytics in a report on Tuesday, March 6th. They issued an “overweight” rating and a $23.00 price objective for the company. Bank of America assumed coverage on shares of Cardlytics in a report on Tuesday, March 6th. They issued a “neutral” rating and a $19.00 price objective for the company. Finally, Wells Fargo & Co began coverage on shares of Cardlytics in a report on Tuesday, March 6th. They issued an “outperform” rating and a $22.00 price objective for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $22.40.

A number of hedge funds and other institutional investors have recently bought and sold shares of CDLX. Polaris Venture Management Co. V L.L.C. acquired a new position in Cardlytics during the 1st quarter worth approximately $38,569,000. Federated Investors Inc. PA acquired a new position in Cardlytics during the 1st quarter worth approximately $5,852,000. BlackRock Inc. acquired a new position in Cardlytics during the 1st quarter worth approximately $3,420,000. Millennium Management LLC acquired a new position in Cardlytics during the 1st quarter worth approximately $2,588,000. Finally, Citadel Advisors LLC acquired a new position in Cardlytics during the 1st quarter worth approximately $1,564,000. Institutional investors own 48.32% of the company’s stock.

Shares of Cardlytics traded up $0.01, reaching $24.45, during trading on Tuesday, Marketbeat reports. The company’s stock had a trading volume of 250,196 shares, compared to its average volume of 142,849. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.68 and a current ratio of 1.68. The stock has a market capitalization of $495.26 million and a P/E ratio of -3.05. Cardlytics has a 1-year low of $11.10 and a 1-year high of $25.71.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardlytics (NASDAQ:CDLX)